Dimensional Fund Advisors LP Grows Stock Position in Evolent Health, Inc. (NYSE:EVH)

Dimensional Fund Advisors LP raised its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 19.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,897,443 shares of the technology company's stock after acquiring an additional 466,225 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.49% of Evolent Health worth $32,595,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Evolent Health during the 4th quarter valued at about $26,000. R Squared Ltd bought a new position in Evolent Health during the fourth quarter valued at approximately $31,000. AlphaQuest LLC grew its holdings in Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after buying an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after acquiring an additional 2,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Evolent Health in the fourth quarter valued at $61,000.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, Director Brendan B. Springstubb acquired 5,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $8.75 per share, with a total value of $43,750.00. Following the completion of the acquisition, the director now directly owns 11,842 shares of the company's stock, valued at approximately $103,617.50. The trade was a 73.08% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Diane Holder acquired 2,735 shares of the business's stock in a transaction on Thursday, March 6th. The stock was acquired at an average price of $9.33 per share, with a total value of $25,517.55. Following the transaction, the director now directly owns 70,584 shares of the company's stock, valued at $658,548.72. This represents a 4.03% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 74,000 shares of company stock worth $666,315. 1.60% of the stock is currently owned by insiders.

Evolent Health Stock Down 16.0%

Shares of Evolent Health stock traded down $1.73 during trading on Friday, hitting $9.05. 5,422,608 shares of the stock were exchanged, compared to its average volume of 2,382,794. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm's 50-day moving average price is $9.61 and its 200 day moving average price is $11.47. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -11.04 and a beta of 1.04. Evolent Health, Inc. has a 12-month low of $8.35 and a 12-month high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). The company had revenue of $483.65 million for the quarter, compared to analyst estimates of $460.15 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The firm's revenue for the quarter was down 24.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS. As a group, analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on EVH shares. Canaccord Genuity Group reduced their price objective on Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Stephens reduced their target price on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Oppenheimer dropped their target price on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. JMP Securities reiterated a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a report on Monday, April 28th. Finally, Royal Bank of Canada cut their price objective on Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Evolent Health presently has an average rating of "Buy" and a consensus price target of $17.79.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.